Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of GSK4527363 in Healthy Participants, SLE, and CTD-ILD
NCT06576271Phase 1Recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of GSK4527363 in systemic lupus erythematosus (SLE) and interstitial lung disease associated with connective tissue disease (CTD-ILD) (10 arms), sponsored by GSK. Primary endpoints: Number of Participants with Non-serious Adverse Events and Serious Adverse Events, Number of Participants with Clinically Significant Changes in Physical Examination, Laboratory Parameters, Vital Signs, and 12 lead Electrocardiogram (ECG) Findings and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
GSK4527363
03
Conditions
systemic lupus erythematosus (SLE)interstitial lung disease associated with connective tissue disease (CTD-ILD)
Beyond the preview
Go deeper on NCT06576271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06576271.